PD-L1 expression in breast cancer brain metastases.
Rania ChehadeMaleeha A QaziMarguerite EnnisArjun SahgalSunit DasSharon Nofech-MozesKatarzyna J JerzakPublished in: Neuro-oncology advances (2022)
One in 7 patients in our cohort had PD-L1 positive BrM; this proportion was highest (25%) among those with TNBC. Intracranial efficacy of immunotherapy warrants further study, particularly among patients with treatment-naïve metastatic TNBC, for whom extracranial efficacy has already been established.